AstraZeneca’s candidate breast cancer therapy Enhertu received a fourth Breakthrough Therapy Designation from the U.S. Food and Drug Administration after the health regulator issued another BTD based on a Phase III trial presented at the European Society for Medical Oncology Congress 2021.

Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.

A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.

Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.

Biopharma companies big and small presented exciting clinical studies at the European Society for Medical Oncology Congress 2021.

AstraZeneca released new results from the company’s ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC), after complete tumor resection.

Roche company Genentech presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Numerous companies presented clinical trial data and updates at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, […]

Immunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.